Treatment of al amyloidosis with melflufen
US12396975B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 3, 2020 |
| Grant date | Aug 26, 2025 |
| Priority date | — |
| Expiry date | Oct 11, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides melflufen, or a salt thereof, or a pharmaceutical formulation comprising melflufen, or a salt thereof, for use in the treatment and/or prophylaxis of immunoglobulin light chain (AL) amyloidosis. The invention also provides dosage regimens and kits that find utility in the treatment and/or prophylaxis of AL amyloidosis, and methods for the treatment and/or prophylaxis of AL amyloidosis, and uses of melflufen, or a salt thereof, for the manufacture of a medicament for the treatment of AL amyloidosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.